Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban

Kengo Noguchi, Yoshiyuki Morishima, Shinichi Takahashi, Hiroaki Ishihara, Toshiro Shibano, Mitsuru Murata

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists. Although this profile of edoxaban suggests it is well suited for clinical use, it is not clear whether genetic variations of factor X influence the activity of edoxaban. Our aim was to investigate a possible impact of single-nucleotide polymorphisms (SNPs) in the factor X gene on the functions of factor X and the activity of edoxaban. Two nonsynonymous SNPs within mature factor X, Ala152Thr and Gly192Arg, were selected as possible candidates that might affect the functions of FXa and the activity of edoxaban. We measured catalytic activities of wild type and mutant FXas in a chromogenic assay using S-2222 and coagulation times including prothrombin time (PT) and activated partial thrombin time (aPTT) of plasma-containing recombinant FXs in the presence and absence of edoxaban. Michaelis-Menten kinetic parameters of FXas, Km and Vmax values, PT and aPTT were not influenced by either mutation indicating these mutations do not affect the FXa catalytic and coagulation activities. The Ki values of edoxaban for the FXas and the concentrations of edoxaban required to double PT and aPTT were not different between wild type and mutated FXas indicating that both mutations have little impact on the activity of edoxaban. In conclusion, these data suggest that edoxaban has little interpatient variability stemming from SNPs in the factor X gene.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume26
Issue number2
DOIs
Publication statusPublished - 2015 Mar 6

Fingerprint

Factor X
Anticoagulants
Mutation
Thrombin Time
Prothrombin Time
Single Nucleotide Polymorphism
Factor Xa
benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide
edoxaban
Vitamin K
Drug Interactions
Pharmaceutical Preparations
Genes
Food

Keywords

  • anticoagulant
  • edoxaban
  • factor Xa
  • factor Xa inhibitor
  • interpatient variability
  • single-nucleotide polymorphisms

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban. / Noguchi, Kengo; Morishima, Yoshiyuki; Takahashi, Shinichi; Ishihara, Hiroaki; Shibano, Toshiro; Murata, Mitsuru.

In: Blood Coagulation and Fibrinolysis, Vol. 26, No. 2, 06.03.2015, p. 117-122.

Research output: Contribution to journalArticle

Noguchi, Kengo ; Morishima, Yoshiyuki ; Takahashi, Shinichi ; Ishihara, Hiroaki ; Shibano, Toshiro ; Murata, Mitsuru. / Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban. In: Blood Coagulation and Fibrinolysis. 2015 ; Vol. 26, No. 2. pp. 117-122.
@article{44e850142b604ae3952db13cb87177f5,
title = "Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban",
abstract = "Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists. Although this profile of edoxaban suggests it is well suited for clinical use, it is not clear whether genetic variations of factor X influence the activity of edoxaban. Our aim was to investigate a possible impact of single-nucleotide polymorphisms (SNPs) in the factor X gene on the functions of factor X and the activity of edoxaban. Two nonsynonymous SNPs within mature factor X, Ala152Thr and Gly192Arg, were selected as possible candidates that might affect the functions of FXa and the activity of edoxaban. We measured catalytic activities of wild type and mutant FXas in a chromogenic assay using S-2222 and coagulation times including prothrombin time (PT) and activated partial thrombin time (aPTT) of plasma-containing recombinant FXs in the presence and absence of edoxaban. Michaelis-Menten kinetic parameters of FXas, Km and Vmax values, PT and aPTT were not influenced by either mutation indicating these mutations do not affect the FXa catalytic and coagulation activities. The Ki values of edoxaban for the FXas and the concentrations of edoxaban required to double PT and aPTT were not different between wild type and mutated FXas indicating that both mutations have little impact on the activity of edoxaban. In conclusion, these data suggest that edoxaban has little interpatient variability stemming from SNPs in the factor X gene.",
keywords = "anticoagulant, edoxaban, factor Xa, factor Xa inhibitor, interpatient variability, single-nucleotide polymorphisms",
author = "Kengo Noguchi and Yoshiyuki Morishima and Shinichi Takahashi and Hiroaki Ishihara and Toshiro Shibano and Mitsuru Murata",
year = "2015",
month = "3",
day = "6",
doi = "10.1097/MBC.0000000000000147",
language = "English",
volume = "26",
pages = "117--122",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban

AU - Noguchi, Kengo

AU - Morishima, Yoshiyuki

AU - Takahashi, Shinichi

AU - Ishihara, Hiroaki

AU - Shibano, Toshiro

AU - Murata, Mitsuru

PY - 2015/3/6

Y1 - 2015/3/6

N2 - Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists. Although this profile of edoxaban suggests it is well suited for clinical use, it is not clear whether genetic variations of factor X influence the activity of edoxaban. Our aim was to investigate a possible impact of single-nucleotide polymorphisms (SNPs) in the factor X gene on the functions of factor X and the activity of edoxaban. Two nonsynonymous SNPs within mature factor X, Ala152Thr and Gly192Arg, were selected as possible candidates that might affect the functions of FXa and the activity of edoxaban. We measured catalytic activities of wild type and mutant FXas in a chromogenic assay using S-2222 and coagulation times including prothrombin time (PT) and activated partial thrombin time (aPTT) of plasma-containing recombinant FXs in the presence and absence of edoxaban. Michaelis-Menten kinetic parameters of FXas, Km and Vmax values, PT and aPTT were not influenced by either mutation indicating these mutations do not affect the FXa catalytic and coagulation activities. The Ki values of edoxaban for the FXas and the concentrations of edoxaban required to double PT and aPTT were not different between wild type and mutated FXas indicating that both mutations have little impact on the activity of edoxaban. In conclusion, these data suggest that edoxaban has little interpatient variability stemming from SNPs in the factor X gene.

AB - Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists. Although this profile of edoxaban suggests it is well suited for clinical use, it is not clear whether genetic variations of factor X influence the activity of edoxaban. Our aim was to investigate a possible impact of single-nucleotide polymorphisms (SNPs) in the factor X gene on the functions of factor X and the activity of edoxaban. Two nonsynonymous SNPs within mature factor X, Ala152Thr and Gly192Arg, were selected as possible candidates that might affect the functions of FXa and the activity of edoxaban. We measured catalytic activities of wild type and mutant FXas in a chromogenic assay using S-2222 and coagulation times including prothrombin time (PT) and activated partial thrombin time (aPTT) of plasma-containing recombinant FXs in the presence and absence of edoxaban. Michaelis-Menten kinetic parameters of FXas, Km and Vmax values, PT and aPTT were not influenced by either mutation indicating these mutations do not affect the FXa catalytic and coagulation activities. The Ki values of edoxaban for the FXas and the concentrations of edoxaban required to double PT and aPTT were not different between wild type and mutated FXas indicating that both mutations have little impact on the activity of edoxaban. In conclusion, these data suggest that edoxaban has little interpatient variability stemming from SNPs in the factor X gene.

KW - anticoagulant

KW - edoxaban

KW - factor Xa

KW - factor Xa inhibitor

KW - interpatient variability

KW - single-nucleotide polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84922396363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922396363&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000147

DO - 10.1097/MBC.0000000000000147

M3 - Article

VL - 26

SP - 117

EP - 122

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 2

ER -